$CLRB
Cellectar Biosciences, Inc.

2015 Q3 Form 10-Q Financial Statement

#000114420415048541 Filed on August 12, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2015 Q2 2014 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $830.0K $820.0K $960.0K
YoY Change 3.75% -14.58% -10.28%
% of Gross Profit
Research & Development $1.168M $1.383M $1.381M
YoY Change -20.58% 0.16% -16.26%
% of Gross Profit
Depreciation & Amortization $90.00K $90.00K $90.00K
YoY Change 0.0% 0.0% -18.18%
% of Gross Profit
Operating Expenses $1.168M $1.383M $1.381M
YoY Change -20.58% 0.16% -16.26%
Operating Profit -$2.093M -$2.291M -$2.546M
YoY Change -7.94% -10.0% -6.5%
Interest Expense $617.00 $449.00 -$114.0K
YoY Change -100.24% -100.39% 5043.05%
% of Operating Profit
Other Income/Expense, Net $234.3K $4.573K $459.8K
YoY Change -90.98% -99.01% -30.14%
Pretax Income -$1.860M -$2.290M -$2.090M
YoY Change -681.25% 9.57% 1.46%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$1.858M -$2.287M -$2.086M
YoY Change -673.49% 9.62% 1.04%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$23.25M -$28.63M -$69.67M
COMMON SHARES
Basic Shares Outstanding 7.564M shares 7.563M shares 57.40M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q3 2015 Q2 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.470M $4.830M $1.630M
YoY Change -78.67% 196.32% -72.04%
Cash & Equivalents $2.473M $4.830M $1.626M
Short-Term Investments
Other Short-Term Assets $510.0K $180.0K $390.0K
YoY Change 45.71% -53.85% 85.71%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $2.973M $5.010M $2.020M
YoY Change -75.06% 148.02% -66.5%
LONG-TERM ASSETS
Property, Plant & Equipment $1.801M $1.890M $2.190M
YoY Change -14.68% -13.7% -12.87%
Goodwill $1.675M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $11.87K $10.00K $10.00K
YoY Change 0.0% 0.0% -63.27%
Total Long-Term Assets $3.489M $3.570M $3.870M
YoY Change -8.16% -7.75% -36.5%
TOTAL ASSETS
Total Short-Term Assets $2.973M $5.010M $2.020M
Total Long-Term Assets $3.489M $3.570M $3.870M
Total Assets $6.462M $8.580M $5.890M
YoY Change -58.9% 45.67% -51.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $580.0K $710.0K $1.070M
YoY Change -49.12% -33.64% 4.9%
Accrued Expenses $130.0K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $240.0K $240.0K $40.00K
YoY Change 118.18% 500.0%
Total Short-Term Liabilities $5.476M $5.840M $4.078M
YoY Change 165.15% 43.21% -33.05%
LONG-TERM LIABILITIES
Long-Term Debt $160.0K $220.0K $4.210M
YoY Change -55.56% -94.77% 835.56%
Other Long-Term Liabilities $150.0K $150.0K $150.0K
YoY Change 0.0% 0.0% 7.14%
Total Long-Term Liabilities $305.8K $367.0K $4.351M
YoY Change -39.46% -91.57% 637.25%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.476M $5.840M $4.078M
Total Long-Term Liabilities $305.8K $367.0K $4.351M
Total Liabilities $5.781M $6.207M $8.429M
YoY Change 124.94% -26.36% 26.16%
SHAREHOLDERS EQUITY
Retained Earnings -$65.56M -$56.09M
YoY Change 15.84%
Common Stock $76.00 $29.00
YoY Change 0.0% -94.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $680.2K $2.370M -$2.541M
YoY Change
Total Liabilities & Shareholders Equity $6.462M $8.580M $5.889M
YoY Change -58.9% 45.71% -51.43%

Cashflow Statement

Concept 2015 Q3 2015 Q2 2014 Q2
OPERATING ACTIVITIES
Net Income -$1.858M -$2.287M -$2.086M
YoY Change -673.49% 9.62% 1.04%
Depreciation, Depletion And Amortization $90.00K $90.00K $90.00K
YoY Change 0.0% 0.0% -18.18%
Cash From Operating Activities -$2.170M -$2.180M -$2.010M
YoY Change 3.33% 8.46% -0.99%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$10.00K $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -190.0K 0.000 -170.0K
YoY Change -101.58% -100.0% 1600.0%
NET CHANGE
Cash From Operating Activities -2.170M -2.180M -2.010M
Cash From Investing Activities -10.00K 0.000 0.000
Cash From Financing Activities -190.0K 0.000 -170.0K
Net Change In Cash -2.370M -2.180M -2.180M
YoY Change -123.84% 0.0% 6.86%
FREE CASH FLOW
Cash From Operating Activities -$2.170M -$2.180M -$2.010M
Capital Expenditures -$10.00K $0.00 $0.00
Free Cash Flow -$2.160M -$2.180M -$2.010M
YoY Change 2.86% 8.46% -0.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
488977 USD
CY2015Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
55000 USD
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
55000 USD
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Trading Symbol
TradingSymbol
CLRB
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7564133 shares
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
220611 USD
CY2014Q4 us-gaap Assets Current
AssetsCurrent
9698238 USD
CY2015Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
712221 USD
CY2015Q2 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
2321 USD
CY2014Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
933988 USD
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
5839832 USD
CY2014Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
5176915 USD
CY2014Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
2180 USD
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6233006 USD
CY2015Q2 us-gaap Notes Payable Current
NotesPayableCurrent
240750 USD
CY2015Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
4884540 USD
CY2015Q2 us-gaap Costs And Expenses
CostsAndExpenses
2291123 USD
CY2015Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
367011 USD
CY2015Q2 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
9233 USD
CY2014Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
11126 USD
CY2014Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
330077 USD
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
147774 USD
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2545617 USD
CY2015Q2 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
4124 USD
CY2015Q2 us-gaap Liabilities
Liabilities
6206843 USD
CY2014Q4 us-gaap Liabilities
Liabilities
6721983 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3026961 USD
CY2015Q2 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
55000 USD
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1382966 USD
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1380798 USD
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
817657 USD
CY2014Q2 us-gaap Restructuring Costs
RestructuringCosts
204934 USD
CY2014Q2 us-gaap Costs And Expenses
CostsAndExpenses
2545617 USD
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2291123 USD
CY2014Q2 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
573751 USD
CY2015Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
449 USD
CY2014Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-113970 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-2286550 USD
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-2085836 USD
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4573 USD
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
459781 USD
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.73
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7562762 shares
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2869739 shares
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3096105 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1761090 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2046921 USD
us-gaap Restructuring Costs
RestructuringCosts
90500 USD
us-gaap Restructuring Costs
RestructuringCosts
221815 USD
us-gaap Costs And Expenses
CostsAndExpenses
4878551 USD
us-gaap Costs And Expenses
CostsAndExpenses
5364841 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-4878551 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-5364841 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1530 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-183214 USD
us-gaap Net Income Loss
NetIncomeLoss
-4587706 USD
us-gaap Net Income Loss
NetIncomeLoss
-5029249 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
290845 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
335592 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.61
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.75
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7562762 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2869739 shares
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
180736 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
188369 USD
us-gaap Share Based Compensation
ShareBasedCompensation
263545 USD
us-gaap Share Based Compensation
ShareBasedCompensation
536216 USD
us-gaap Other Noncash Expense
OtherNoncashExpense
0 USD
us-gaap Other Noncash Expense
OtherNoncashExpense
50805 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-858 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-2268 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-221767 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
33320 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-102022 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-132115 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4553608 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4602340 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15191 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-33665 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-15191 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
4000000 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1752 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1263 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-2077 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
33665 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
3825172 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4589350 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-792359 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2418384 USD
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1626025 USD
clrb Debt Conversion Converted Instrument Value Warrants Issued
DebtConversionConvertedInstrumentValueWarrantsIssued
0 USD
clrb Debt Conversion Converted Instrument Value Warrants Issued
DebtConversionConvertedInstrumentValueWarrantsIssued
254024 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-2622 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-1079 USD
us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.9 pure
us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P2Y7M20D
CY2014Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
13475832 USD
CY2014Q3 us-gaap Proceeds From Repurchase Of Equity
ProceedsFromRepurchaseOfEquity
11877143 USD
CY2014Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1598689 USD
CY2015Q2 us-gaap Share Based Compensation
ShareBasedCompensation
71755 USD
CY2014Q2 us-gaap Share Based Compensation
ShareBasedCompensation
273690 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
510200 shares
clrb Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
-105072 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
-229475 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
895119 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
719466 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.59
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.47
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.65
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
315203 shares
CY2015Q2 clrb Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Unvested Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedOutstandingNumber
579916 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
315203 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
18.14
CY2015Q2 clrb Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedExercisableWeightedAverageExercisePrice
3.21
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
18.14
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
7969 USD
CY2015Q2 clrb Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue
110269 USD
CY2015Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
7969 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y3M29D
clrb Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingWeightedAverageRemainingContractualTerm
P9Y8M23D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y3M29D
clrb Amount Invoiced Under Clinical Trial Agreements
AmountInvoicedUnderClinicalTrialAgreements
417813 USD
clrb Payment Towards Clinical Trial Agreements
PaymentTowardsClinicalTrialAgreements
415613 USD
CY2015Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2015Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000 shares
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000 shares
CY2015Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
us-gaap Interest Paid
InterestPaid
0 USD
CY2015Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
5494388 shares
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7562762 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7562762 shares
us-gaap Interest Paid
InterestPaid
22594 USD
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7562762 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7562762 shares
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 USD
CY2014Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
5494388 shares
CY2014Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
55000 USD
us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0088 pure
CY2015Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
6604096 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.08 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0176 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.40
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.20
CY2015Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1421000 USD
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Current Year
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInCurrentYear
335000 USD
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Two
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearTwo
459000 USD
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Three
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearThree
331000 USD
CY2015Q2 clrb Share Based Compensation Arrangement By Sharebased Payment Award Options Unvested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestOutstandingNumber
579916 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
50000 shares
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Four
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearFour
206000 USD
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Five
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearFive
90000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
325 USD
clrb Proceeds From Deferred Issuance Costs
ProceedsFromDeferredIssuanceCosts
0 USD
clrb Proceeds From Deferred Issuance Costs
ProceedsFromDeferredIssuanceCosts
-172407 USD
clrb Reverse Stock Split Fractional Shares
ReverseStockSplitFractionalShares
0 USD
clrb Reverse Stock Split Fractional Shares
ReverseStockSplitFractionalShares
1158 USD
clrb Share Based Compensation Arrangements By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice
27.22
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
9.29

Files In Submission

Name View Source Status
0001144204-15-048541-index-headers.html Edgar Link pending
0001144204-15-048541-index.html Edgar Link pending
0001144204-15-048541.txt Edgar Link pending
0001144204-15-048541-xbrl.zip Edgar Link pending
clrb-20150630.xml Edgar Link completed
clrb-20150630.xsd Edgar Link pending
clrb-20150630_cal.xml Edgar Link unprocessable
clrb-20150630_def.xml Edgar Link unprocessable
clrb-20150630_lab.xml Edgar Link unprocessable
clrb-20150630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v417441_10q.htm Edgar Link pending
v417441_ex10-1.htm Edgar Link pending
v417441_ex10-2.htm Edgar Link pending
v417441_ex10-3.htm Edgar Link pending
v417441_ex31-1.htm Edgar Link pending
v417441_ex31-2.htm Edgar Link pending
v417441_ex32-1.htm Edgar Link pending